Verastem Oncology is a commercial-stage biopharmaceutical company (NASDAQ: VSTM) developing medicines to improve the lives of patients with cancer, with a focus on RAS/MAPK pathway-driven tumors and hematologic cancers. Lead marketed product is Avmapki Fakzynja Co-Pack (avutometinib + defactinib) for KRAS-mutated recurrent low-grade serous ovarian cancer.
Strategic review of oncology combo following RAMP pancreatic readout
Updated Avmapki Fakzynja commercial launch metrics in LGSOC
Verastem reported a 'robust' response rate for its RAS-directed drug in a pancreatic cancer subgroup - a setting where analysts see a more specific agent outperforming Revolution Medicines' recently approved Rasonque.
Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Verastem mulls options on approved asset in pancreatic cancer.
President & Chief Executive Officer